Latest Rosiglitazone Stories

2009-03-31 06:50:00

Federal health officials are examining a potentially ground breaking diabetes medication from Bristol-Myers Squibb because it appears free of heart-related side effects that have plagued similar treatments. The Food and Drug Administration will still ask an outside panel to scrutinize the company's safety data at a meeting Wednesday. Bristol-Myers and partner AstraZeneca want the FDA to approve Onglyza, which promises to decrease blood sugar levels in patients with type 2 diabetes. Type 2...

2009-03-26 08:00:00

ST. PAUL, Minn., March 26 /PRNewswire/ -- Pharmacy benefit manager Prime Therapeutics (Prime) announced that three of its clinical pharmacists, Patrick Gleason, PharmD, FCCP, BCPS, Cathy Starner, PharmD and Jeremy Schafer, PharmD were awarded the Journal of Managed Care Pharmacy (JMCP) Award of Excellence for their manuscript assessing rosiglitazone and pioglitazone utilization trends and associated medical and pharmacy claims data indicating risk for an adverse cardiovascular event. Prime's...

2009-02-24 05:00:00

NEW YORK, Feb. 24 /PRNewswire/ -- Mindset BioPharmaceuticals (USA) Inc ("MINDSET") a company privately held by MPM Capital and other shareholders announced today that it has received a Notice of Allowance in Europe related to patent applications describing the use of insulin sensitizer drugs for the prevention and treatment of memory loss. Drugs of this type include Rosiglitazone and Pioglitazone which have been approved for the treatment of type II diabetes mellitus. Glucose is used by...

2009-01-21 08:00:00

Basis Established for DNA-Guided Decision Support in Diabetes Drug Therapy HARTFORD, Conn., Jan. 21 /PRNewswire/ -- Research by Genomas has shown statistically significant associations of certain genes in vascular and energy pathways to body mass index (BMI) and edema (fluid retention) in patients taking the thiazolidinedione (TZD) drugs pioglitazone and rosiglitazone. The study, co-authored with investigators from Joslin Diabetes Center Affiliate at The Hospital of Central Connecticut,...

2009-01-08 14:10:00

LOS ALTOS, Calif., Jan. 8 /PRNewswire/ -- InteKrin Therapeutics, Inc., will present at the 27th Annual JP Morgan Global Healthcare Conference at 9:00 a.m. Pacific Time on Tuesday, January 13, 2009, to be held at the Westin St. Francis in San Francisco, California. InteKrin Therapeutics' President and CEO Denny Lanfear will present at the conference. About InteKrin (http://www.InteKrin.com): InteKrin Therapeutics is a privately-held clinical stage biopharmaceutical company...

2008-12-10 14:20:00

A study released on Wednesday shows that long-term use of GlaxoSmithKline's Avandia and Takeda's Actos doubles the risk of bone fractures in women with type 2 diabetes. The two thiazolidinedione (TZD) drugs for diabetes were known for some time to be associated with fractures, but the magnitude of the risk had not been evaluated until now. "Women with type 2 diabetes are already at an increased risk of fractures, so any additional risk from thiazolidinedione therapy could have a considerable...

2008-12-04 08:13:31

A medication for diabetics may do more harm than good. Doctors are concerned rosiglitazone may increase older patients' risk of death and heart failure.A black box warning was recently added to two drugs, rosiglitazone and pioglitazone hydrochloride, cautioning patients with heart failure against using them. Recent studies have shown the risks linked to rosiglitazone are even greater than those associated with pioglitazone.Researchers at Brigham and Women's Hospital and Harvard Medical School...

2008-11-13 09:05:00

New findings support the claim that a controversial diabetes pill failed to significantly slow plaque buildup in heart arteries compared with an older drug. Since May of last year, Avandia, once a blockbuster drug made by British-based GlaxoSmithKline PLC, has been under a dark cloud of doubt. That's because a medical journal report suggested it could raise the risk of heart attacks and heart-related deaths; the American Diabetes Association recently said patients should avoid using it...

2008-10-31 10:30:00

Public Citizen, a consumer advocate group, has called on the U.S. to ban sales and distribution of the diabetes drug Avandia due to certain risks found to be linked with the drug. New research released by Public Citizen about the drug, used to treat Type 2 diabetes, comes as a working group with representatives from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes, unanimously advised against using Avandia, whose generic name is rosiglitazone,...

2008-10-30 21:00:11

PHILADELPHIA, Oct. 30 /PRNewswire-FirstCall/ -- GlaxoSmithKline today issued the following response to a petition filed by Public Citizen to the U.S. Food and Drug Administration (FDA) on AVANDIA(R) (rosiglitazone maleate), a highly effective therapy for treating type 2 diabetes when used in the appropriate patient population. The safety of patients using our medicine is very important to us. On a continual basis, an external Hepatic Safety Board reviews any adverse event report received...

Word of the Day
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'